OpenAI launches GPT-Rosalind for life sciences research

OpenAI has unveiled GPT-Rosalind, a specialized AI model aimed at accelerating drug discovery and life sciences research by streamlining complex workflows. This new model is designed to act as a domain-specific reasoning partner, capable of synthesizing evidence, generating hypotheses, and planning experiments, tasks that typically require extensive human expertise and time. GPT-Rosalind has demonstrated strong performance on scientific benchmarks, outperforming previous models in areas like bioinformatics and molecular cloning protocol design. OpenAI is releasing it through a trusted access program for qualified enterprise customers, emphasizing governance and beneficial use.